

# Active Approach to Health Care Investing

## Simplify Health Care ETF (PINK)


Seeks capital appreciation through multi-cap exposure to innovative companies in biotech, med-tech, gene therapy, and other fast growing health care related sectors.

Hedge fund veteran and former scientist Mike Taylor uses his deep understanding of the sector to take a highly active approach. 100% of the profits are donated to the Susan G. Komen Foundation for breast cancer.



Total donations since inception  
 ♥ **\$350,000**  
 as of 03/31/26

### PINK vs. MSCI USA IMI Health Care Net Total Return USD Index 10/07/21 - 03/31/26



The data quoted represents past performance and is no guarantee of future results. Current yield and duration may be lower or higher than the performance data quoted. Investment returns and the principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. For performance data current to the most recent month-end please call (855) 772-8488 or go to: [simplify.us/etfs](https://simplify.us/etfs). For standardized performance, go to: [simplify.us/etfs/pink-simplify-health-care-etf](https://simplify.us/etfs/pink-simplify-health-care-etf).



Scan the QR Code to Learn More About  
**PINK** | Simplify Health Care ETF

Performance as of 03/31/26 | Inception Date: 10/07/21

	Cumulative Total Return (%)							Annualized Total Return (%)			
	3 Months	6 Months	1 Year	3 Year	5 Year	YTD	Since Inception	1 Year	3 Year	5 Year	Since Inception
NAV	-7.99	6.35	15.30	36.50	—	-7.99	37.97	15.30	10.93	—	7.45
Market Price	-7.90	6.60	15.71	37.00	—	-7.90	38.76	15.71	11.06	—	7.59
MSCI USA IMI Health Care Net Total Return USD Index	-5.01	5.77	4.25	18.30	—	-5.01	15.67	4.25	5.76	—	3.30

Expense Ratio (%)	0.51%
-------------------	-------

The performance data quoted represents past performance and does not guarantee future results. Current performance may be lower or higher than the performance data quoted. In addition, investment returns and the principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. For performance data current to the most recent month-end, please call (855) 772-8488 or go to: [simplify.us/etfs](https://simplify.us/etfs).

**DEFINITIONS:**

**MSCI USA IMI Health Care Net Total Return USD Index:** Designed to capture the large and mid cap segments of the US equity universe. All securities in the index are classified in the Health Care sector as per the Global Industry Classification Standard (GICS®).

**Investors should carefully consider the investment objectives, risks, charges, and expenses of Exchange Traded Funds (ETFs) before investing. To obtain an ETF's prospectus or Summary prospectus containing this and other important information, please call (855) 772-8488, or visit [SimplifyETFs.com](https://SimplifyETFs.com). Please read the prospectus carefully before you invest.**

**An investment in the fund involves risk, including possible loss of principal.**

The fund is actively-managed and is subject to the risk that the strategy may not produce the intended results.

The Fund focuses its investments in securities of biotechnology and the healthcare industry. Economic, legislative or regulatory developments may occur that significantly affect these industries and cause the Fund's net asset value to fluctuate due to this concentration.

The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits.

In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized have limited product lines, distribution channels, resources and more volatile than companies with greater capitalizations. Biotechnology companies must contend with high development costs, which may be exacerbated by the inability to raise prices to cover costs because of managed care pressure, government regulation or price controls. Companies in the pharmaceutical industry are heavily dependent on patent protection. The expiration of patents may adversely affect the profitability of the companies. Pharmaceutical companies are also subject to extensive litigation based liability and approval of the Food and Drug Administration, a process that can be long and costly. Expanding international operations may lead to risks resulting from differences between U.S. and foreign legal, political and economic systems, regulatory regimes and market practices.

The Fund's focus on the healthcare sector may cause its value to fluctuate and be more susceptible to particular risks of the sector such as extensive government regulations, restrictions on government reimbursement for medical expenses, rising costs of medical products and services, pricing pressure, an increased emphasis on outpatient services, changes in the demand for medical products and services, a limited number of products, industry innovation, changes in technologies and other market developments.

Simplify ETFs are distributed by Foreside Financial Services, LLC. Simplify and Foreside are not related.

© 2026 Simplify ETFs. All rights reserved.